Public Company News

PMET Resources Delivers Positive CV5 Lithium-Only Feasibility Study for its Large-Scale Shaakichiuwaanaan Project

Unlocking Shaakichiuwaanaan's maiden Mineral Reserve and a key step towards final mine authorisation MONTREAL, Oct. 21, 2025 /PRNewswire/ -- October 21, 2025 – Sydney, Australia Highlights * Robust CV5 lithium-only Feasibility Study ("FS") completed on the Shaakichiuwaanaan Project (Project) ...

2025-10-21 05:45 1031

SM Investments certified as a Great Place to Work® in 2025

PASAY CITY, Philippines , Oct. 20, 2025 /PRNewswire/ -- SM Investments Corporation (SM Investments), the parent company of the SM group, has been certified as a Great Place to Work for 2025 by the global authority on workplace culture, Great Place to Work®. 

2025-10-20 20:45 1615

IBM and Groq Partner to Accelerate Enterprise AI Deployment with Speed and Scale

Partnership aims to deliver faster agentic AI capabilities through IBM watsonx Orchestrate and Groq technology, enabling enterprise clients to take immediate action on complex workflows ARMONK, N.Y. and MOUNTAIN VIEW, Calif., Oct. 20, 2025 /PRNewswire/ -- IBM (NYSE:IBM

2025-10-20 18:09 1362

SKF at COP30: The world can't afford friction - it's time to scale what works

GOTHENBURG, Sweden, Oct. 20, 2025 /PRNewswire/ -- SKF will be attending COP30, held in Belém,Brazil in November 2025, to drive systemic change and progress through collaboration. A resilient industry demands open, systematic collaboration. SKF sees friction every day, in mindsets, metrics, and b...

2025-10-20 17:54 1112

Tiger Brokers (Hong Kong) Sponsors CFA Institute Research Challenge -- Hong Kong Local Final for the First Time, Introducing the "Star Presenter" Award

HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Tiger Brokers (Hong Kong) Global Limited ("Tiger Brokers (Hong Kong)") is proud to announce its inaugural sponsorship of the 2025–2026 CFA Institute Research Challenge — Hong Kong Local Final, underscoring the firm's commitment to talent development, profe...

2025-10-20 17:40 2028

The New England Journal of Medicine Publishes Results of Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan in Advanced EGFR-TKI-Resistant NSCLC

* After a median follow-up of 18.9 months, the median PFS was 8.3 months in the sac-TMT group and 4.3 months in the chemotherapy group (hazard ratio (HR), 0.49; 95% confidence interval (CI), 0.39 to 0.62; two-sided P<0.0001). * OS was significantly longer with sac-TMT than with chemotherapy (H...

2025-10-20 17:06 1581

Global Chinese Wealth Manager Noah Holdings Hosts Inaugural N+ Art Club Exhibition in Shanghai: Hub: The Endless Exploration of Art

Extending Trust Between Cultures & Generations Through "Wisdom • Wealth • A Life of Warmth" SHANGHAI, Oct. 20, 2025 /PRNewswire/ -- Noah Holdings Limited ("Noah" or the "Company") (NYSE: NOAH and HKEX: 6686), a leading and pioneer wealth management service provider offering comprehensive one-sto...

2025-10-20 16:53 3124

ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016)...

2025-10-20 14:58 1845

3M at China Wind Power 2025: innovations empowering the future of green energy

BEIJING, Oct. 20, 2025 /PRNewswire/ -- On October 20, 2025, 3M, a global leader in diversified technology, made its appearance at the 2025 China Wind Power (CWP 2025). At this year's exhibition, 3M's booth theme was "With Wind as Wings, 3M Empowers a Green Future," focusing on showcasing innovativ...

2025-10-20 14:16 1551

Agoda Spotlights Unique Asian Airports Redefining the Layover Experience

SINGAPORE, Oct. 20, 2025 /PRNewswire/ -- Digital travel platform Agoda has unveiled a list of five airports inAsia that transform layovers into memorable experiences. These airports offer more than just transit, with attractions that cater to both short and long stops, inviting travelers to arriv...

2025-10-20 14:03 1250

Kelun-Biotech Presents Positive Phase 3 Data for Trastuzumab Botidotin Compared to T-DM1 at 2025 ESMO

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, Results from a Phase 3 study of the Company's human epidermal growth factor rece...

2025-10-20 13:59 1583

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrou...

2025-10-20 13:21 1411

Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colore...

2025-10-20 13:15 1654

KLN Drives Libya's Wellhead Platform A Project Toward Completion, One of the Mediterranean Sea's Largest Offshore EPCI Projects to Bolster Energy Infrastructure

HONG KONG, Oct. 20, 2025 /PRNewswire/ -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK), through its division KLN Project, today announced significant progress on the Wellhead Platform A (WHPA) project inLibya's Bahr Essalam field.  As consortium leader appointed by Mellitah Oil & Gas Co...

2025-10-20 12:29 1467

Nongshim Shin Ramyun Light Ups New York Times Square with 'KPop Demon Hunters'

- Global campaign celebrates the U.S. debut of the movie-inspired collaboration package - NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Nongshim carried out a global campaign at New York Times Square to celebrate the launch of Shin Ramyun in collaboration with Netflix's hit animated film 'KPop Demon H...

2025-10-20 11:23 1485

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-s...

2025-10-20 10:36 1863

Agoda and Premier Inn Partner to Capture Rising Asian Traveler Interest in UK and Europe

The partnership aims to connect travelers from Asia and beyond to over 900 properties across the UK,Germany and Ireland SINGAPORE, Oct. 20, 2025 /PRNewswire/ -- Global digital travel platform Agoda has announced a new partnership with theUnited Kingdom's (UK) largest hotel chain Premier Inn maki...

2025-10-20 10:30 1574

Save Now, Travel through March: T'way Air Announces Fall Savings to Korea

Promo Code FLYOCT & Special Coupons for Travel through March 2026 TAIPEI, Oct. 20, 2025 /PRNewswire/ -- T'way Air, Korea's leading low-cost carrier, invites travelers to enjoy special savings throughOctober 31 on Taiwan-Korea bookings for travel untilMarch 28, 2026.

2025-10-20 09:00 1897

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...

2025-10-20 09:00 2228

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

-          The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) ofsmall molecule GLP-1 receptor (GLP-1R) agonist ASC30  in 65 participants with obesity or overweight. -          The ult...

2025-10-20 08:10 1929
1 ... 81828384858687 ... 893

Week's Top Stories